About tonix pharmaceuticals holding corp - TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.
TNXP At a Glance
Tonix Pharmaceuticals Holding Corp.
200 Connell Drive
Berkeley Heights, New Jersey 07922
| Phone | 1-862-799-8599 | Revenue | 13.11M | |
| Industry | Pharmaceuticals: Major | Net Income | -124,021,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 29.849% | |
| Fiscal Year-end | 12 / 2026 | Employees | 142 | |
| View SEC Filings |
TNXP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.143 |
| Price to Book Ratio | 0.815 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.593 |
| Enterprise Value to Sales | -5.599 |
| Total Debt to Enterprise Value | -0.018 |
TNXP Efficiency
| Revenue/Employee | 92,302.817 |
| Income Per Employee | -873,387.324 |
| Receivables Turnover | 1.343 |
| Total Asset Turnover | 0.06 |
TNXP Liquidity
| Current Ratio | 7.422 |
| Quick Ratio | 7.227 |
| Cash Ratio | 6.733 |
TNXP Profitability
| Gross Margin | 34.653 |
| Operating Margin | -959.052 |
| Pretax Margin | -946.22 |
| Net Margin | -946.22 |
| Return on Assets | -56.365 |
| Return on Equity | -64.475 |
| Return on Total Capital | -50.321 |
| Return on Invested Capital | -63.451 |
TNXP Capital Structure
| Total Debt to Total Equity | 0.534 |
| Total Debt to Total Capital | 0.531 |
| Total Debt to Total Assets | 0.472 |
| Long-Term Debt to Equity | 0.483 |
| Long-Term Debt to Total Capital | 0.48 |